Company Overview
| Stock Name | Purapharm |
|---|---|
| Stock Code | 01498 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 以香港為基地的領先中醫藥公司,以「農本方®」品牌從事濃縮中藥配方顆粒產品的研發、生產、市場推廣及銷售,並銷售金靈芝®及安固生®等中藥保健品。 |
| Listing Date | 2015-07-08 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 香港新界大埔香港科學園1期無線電中心2樓201-207單位 |
| Business Address (Hong Kong) | 香港中環康樂廣場1號怡和大廈4002室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | purapharm.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 5.98 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | 71,130,000 shares |
| HK Public Offer Shares (Initial) | 7,113,000 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 64,017,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 225,000,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 425,357,400 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 148.2M |
| Est. Threshold | HK$ 9.71B |
| Analysis Result | HK market cap below threshold, need +6454% |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約34.5百萬港元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | ~HK$ 46,800,000 |
| Listing Expenses / Funds Raised | ~11.0% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
HKD
Income Statement
| Item | 2012 | 2013 | 2014 |
|---|---|---|---|
| Revenue | 287,811 | 342,303 | 366,352 |
| Cost of sales | -103,210 | -123,086 | -134,241 |
| Gross profit | 184,601 | 219,217 | 232,111 |
| Other income and gains, net | 13,996 | 7,956 | 5,794 |
| Selling and distribution expenses | -78,166 | -101,940 | -99,176 |
| Administrative expenses | -54,628 | -79,711 | -81,028 |
| Operating profit | 61,012 | 42,839 | 55,394 |
| Net finance costs | -10,959 | -13,149 | -13,064 |
| Profit before tax | 50,053 | 29,690 | 42,330 |
| Income tax expense | -5,911 | -3,399 | -7,823 |
| Profit for the year | 44,142 | 26,291 | 34,507 |
| Profit attributable to owners | 44,094 | 26,264 | 34,463 |
Balance Sheet
| Item | 2012 | 2013 | 2014 |
|---|---|---|---|
| Cash and cash equivalents | 36,839 | 32,852 | 46,736 |
| Trade and bills receivables | 67,326 | 98,744 | 103,098 |
| Inventories | 76,943 | 65,214 | 89,893 |
| Total current assets | 236,066 | 240,214 | 305,606 |
| Total assets | 333,502 | 348,111 | 420,310 |
| Total current liabilities | 286,806 | 268,440 | 282,575 |
| Total liabilities | 289,475 | 274,999 | 284,497 |
| Total equity | 44,027 | 73,112 | 135,813 |
| Equity attributable to owners | 43,974 | 73,032 | 135,689 |
| Interest-bearing borrowings | 179,839 | 188,190 | 182,692 |
Cash Flow Statement
| Item | 2012 | 2013 | 2014 |
|---|---|---|---|
| Net cash from operating activities | 62,128 | 11,034 | 31,091 |
| Net cash from investing activities | -37,793 | -6,268 | -24,634 |
| Net cash from financing activities | 2,165 | 2,355 | -259 |
| Net increase in cash | 26,500 | 7,121 | 6,198 |
| Depreciation of PP&E | 9,840 | 11,346 | 12,749 |
| Amortisation of intangible assets | 394 | 621 | 837 |
| Purchase of PP&E | -13,426 | -17,187 | -8,586 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 3.83 |
|---|---|
| First Day Open | HK$ 4.77 |
| First Day Change | -35.95% |
| First Day Volume | 20735500.0 |
| First Day Turnover | 85492600.0 |
| Use of Proceeds | 1、約30.0%或86.7百萬港元將用作擴建生產設施及為現有生產線進行升級;
2、約25.0%或72.2百萬港元將用作在香港及中國成立新的農本方?中醫診所;
3、約20.0%或57.8百萬港元用作擴展我們的分銷網絡至中國的新目標城市,主要透過與國藥控股合作付諸實行,包括:(i)為新客戶購買農本方?智能中醫診所管理及配藥系統設備(每個藥房系統的平均成本為150,000港元);(ii)就農本方?智能中醫診所管理及配藥系統的運營及維護培訓新的分銷商及醫院員工;(iii)提供售后及維護服務;(iv)在中國的獲批準醫院及醫療機構成立及裝修我們從事直接銷售的中藥房;
4、約15.0%或43.3百萬港元用作為下列兩種新中成藥產品的開發及推廣(包括:(i)完成中國規定的臨床試驗;(ii)香港及中國的新產品注冊;及(iii)有關測試、抽樣及項目管理)提供資金;
5、約10.0%或28.9百萬港元將用作我們的營運資金及其他一般公司用途。 |
Underwriting Syndicate
Sole Sponsor (1)
BOCOM International (Asia) Limited CE API271
Overall Coordinators (1)
交银国际证券有限公司 CE APJ121
Joint Bookrunners (1)
交银国际证券有限公司 CE APJ121
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 陳宇齡 | — |
| Company Secretary | 鄭學啟 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 陳宇齡先生及文綺慧女士透過Purapharm Corp.、Fullgold Development及Joint Partners間接實益擁有合共57.28%權益;Fullgold Development持股34.35%,PuraPharm Corp.及Joint Partners各持股22.93%。 |
|---|




